The effect of topical diclofenac 3% and calcitriol 3 μg/g on superficial basal cell carcinoma (sBCC) and nodular basal cell carcinoma (nBCC): A phase II, randomized controlled trial
Autor: | Kiki J. A. Frencken, Axel zur Hausen, Tjinta Brinkhuizen, Véronique Winnepenninckx, Maurice A.M. van Steensel, Dorit Rennspiess, Patricia J. Nelemans, Michiel P. J. van der Horst, Klara Mosterd, Nicole W.J. Kelleners-Smeets, Marlou L. S. Hoff |
---|---|
Přispěvatelé: | MUMC+: MA AIOS Dermatologie (9), Promovendi ODB, Dermatologie, Epidemiologie, RS: CAPHRI - R5 - Optimising Patient Care, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, MUMC+: MA Dermatologie (9), MUMC+: DA Klinische Pathologie (5), Pathologie, RS: GROW - R2 - Basic and Translational Cancer Biology, MUMC+: DA Pat Pathologie (9) |
Rok vydání: | 2015 |
Předmět: |
Male
Pathology Skin Neoplasms Administration Topical vitamin D Apoptosis Gastroenterology law.invention Ointments 030207 dermatology & venereal diseases 0302 clinical medicine Randomized controlled trial law Medicine Single-Blind Method topical Anti-Inflammatory Agents Non-Steroidal Diclofenac Sodium Vitamins Middle Aged targeted therapy Treatment Outcome Proto-Oncogene Proteins c-bcl-2 030220 oncology & carcinogenesis Drug Therapy Combination Female medicine.drug medicine.medical_specialty Diclofenac Calcitriol Combination therapy Dermatology Medication Adherence 03 medical and health sciences basal cell carcinoma Internal medicine noninvasive Humans Basal cell carcinoma Adverse effect Aged Cell Proliferation nonsteroidal anti-inflammatory drugs business.industry medicine.disease Lymphoma stomatognathic diseases Ki-67 Antigen Carcinoma Basal Cell business Gels |
Zdroj: | Journal of the American Academy of Dermatology, 75(1), 126-134. MOSBY-ELSEVIER |
ISSN: | 1097-6787 0190-9622 |
Popis: | Background: Nonsteroidal anti-inflammatory drugs and vitamin-D derivatives can target signaling pathways activated in basal cell carcinoma (BCC). Objective: We investigated the efficacy of topically applied diclofenac sodium 3% gel, calcitriol 3 mu g/g ointment, and a combination of both in superficial BCC (sBCC) and nodular BCC. Methods: Patients with a primary, histologically proven sBCC (n = 64) or nodular BCC (n = 64) were randomized to topical diclofenac, calcitriol, combination of both, or no topical treatment (control group). After self-application twice daily under occlusion (8 weeks), tumors were excised. Primary outcome was posttreatment expression levels of proliferation (Ki-67) and antiapoptosis (B-cell lymphoma [Bcl-2]) immunohistochemical markers. Secondary outcomes were histologic clearance, adverse events, application-site reactions, and patient compliance. Results: sBCC treated with diclofenac showed a significant decrease in Ki-67 (P |
Databáze: | OpenAIRE |
Externí odkaz: |